Seroatlas · Human Serome Atlas

ARHGAP31

Rho GTPase-activating protein 31

Also known as: CDGAP, RHG31_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q2M1Z3
Gene: ARHGAP31
Ensembl: ENSG00000031081
Chromosome: 3
Canonical length: 1444 aa
Protein class: Disease related genes, Human disease related genes, Predicted intracellular proteins

OverviewNCBI Gene

This gene encodes a GTPase-activating protein (GAP). A variety of cellular processes are regulated by Rho GTPases which cycle between an inactive form bound to GDP and an active form bound to GTP. This cycling between inactive and active forms is regulated by guanine nucleotide exchange factors and GAPs. The encoded protein is a GAP shown to regulate two GTPases involved in protein trafficking and cell growth. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

1444 residues, UniProt reviewed canonical sequence.

>Q2M1Z3|ARHGAP31
     1  MKNKGAKQKL KRKGAASAFG CDLTEYLESS GQDVPYVLKS CAEFIETHGI VDGIYRLSGV
    61  TSNIQRLRQE FGSDQCPDLT REVYLQDIHC VGSLCKLYFR ELPNPLLTYE LYEKFTEAVS
   121  HCPEEGQLAR IQNVIQELPP SHYRTLEYLI RHLAHIASFS SKTNMHARNL ALVWAPNLLR
   181  SKEIEATGCN GDAAFLAVRV QQVVIEFILN HVDQIFNNGA PGSLENDENR PIMKSLTLPA
   241  LSLPMKLVSL EEAQARSLAT NHPARKERRE NSLPEIVPPM GTLFHTVLEL PDNKRKLSSK
   301  SKKWKSIFNL GRSGSDSKSK LSRNGSVFVR GQRLSVEKAT IRPAKSMDSL CSVPVEGKET
   361  KGNFNRTVTT GGFFIPATKM HSTGTGSSCD LTKQEGEWGQ EGMPPGAEGG FDVSSDRSHL
   421  QGAQARPPPE QLKVFRPVED PESEQTAPKM LGMFYTSNDS PSKSVFTSSL FQMEPSPRNQ
   481  RKALNISEPF AVSVPLRVSA VISTNSTPCR TPPKELQSLS SLEEFSFHGS ESGGWPEEEK
   541  PLGAETSAAS VPKKAGLEDA KAVPEAPGTV ECSKGLSQEP GAHLEEKKTP ESSLSSQHLN
   601  ELEKRPNPEK VVEEGREAGE MESSTLQESP RARAEAVLLH EMDEDDLANA LIWPEIQQEL
   661  KIIESEEELS SLPPPALKTS PIQPILESSL GPFIPSEPPG SLPCGSFPAP VSTPLEVWTR
   721  DPANQSTQGA STAASREKPE PEQGLHPDLA SLAPLEIVPF EKASPQATVE VGGPGNLSPP
   781  LPPAPPPPTP LEESTPVLLS KGGPEREDSS RKLRTDLYID QLKSQDSPEI SSLCQGEEAT
   841  PRHSDKQNSK NAASEGKGCG FPSPTREVEI VSQEEEDVTH SVQEPSDCDE DDTVTDIAQH
   901  GLEMVEPWEE PQWVTSPLHS PTLKDAHKAQ VQGLQGHQLE KRLSHRPSLR QSHSLDSKPT
   961  VKSQWTLEVP SSSSCANLET ERNSDPLQPQ APRREITGWD EKALRSFREF SGLKGAEAPP
  1021  NQKGPSGVQP NPAETSPISL AEGKELGTHL GHSSPQIRQG GVPGPESSKE SSPSVQDSTS
  1081  PGEHPAKLQL KSTECGPPKG KNRPSSLNLD PAIPIADLFW FENVASFSSP GMQVSEPGDP
  1141  KVTWMTSSYC KADPWRVYSQ DPQDLDIVAH ALTGRRNSAP VSVSAVRTSF MVKMCQARAV
  1201  PVIPPKIQYT QIPQPLPSQS SGENGVQPLE RSQEGPSSTS GTTQKPAKDD SPSSLESSKE
  1261  EKPKQDPGAI KSSPVDATAP CMCEGPTLSP EPGSSNLLST QDAVVQCRKR MSETEPSGDN
  1321  LLSSKLERPS GGSKPFHRSR PGRPQSLILF SPPFPIMDHL PPSSTVTDSK VLLSPIRSPT
  1381  QTVSPGLLCG ELAENTWVTP EGVTLRNKMT IPKNGQRLET STSCFYQPQR RSVILDGRSG
  1441  RQIE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ARHGAP31 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.63
Highest tissue expression: 18 nTPM

Expression across tissuesHPA

Tissue

lung: 18 nTPM
adipose tissue: 16 nTPM
heart muscle: 12 nTPM
thyroid gland: 12 nTPM
smooth muscle: 11 nTPM
placenta: 11 nTPM

Single-cell type

bergmann glia: 585 nCPM
vascular endothelial cells: 398 nCPM
oligodendrocyte progenitor cells: 296 nCPM
cdc: 283 nCPM
microglia: 259 nCPM
astrocytes: 208 nCPM

Immune cell

myeloid DC: 6 nTPM
plasmacytoid DC: 5.2 nTPM
intermediate monocyte: 2.8 nTPM
classical monocyte: 2.6 nTPM
memory B-cell: 1.6 nTPM
total PBMC: 1.2 nTPM

Brain region

medulla oblongata: 33 nTPM
thalamus: 32 nTPM
midbrain: 31 nTPM
cerebellum: 30 nTPM
white matter: 29 nTPM
pons: 28 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ARHGAP31.

Disease | AllUniProt

Conditions ARHGAP31 is implicated in, by any mechanism.

Adams-Oliver syndrome 1 (AOS1) MIM:100300

Disease | GeneticClinVar

4 pathogenic / likely-pathogenic of 665 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Adams-Oliver syndrome 1
Cerebral palsy

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.19
gnomAD pLI: 1
gnomAD missense Z: 0.8
DepMap mean gene effect: -0.04
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ARHGAP31 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ARHGAP31 as an antibody target. Whether an autoantibody or antibody against ARHGAP31 could matter depends on whether native ARHGAP31 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ARHGAP31 is annotated at the cell surface, where native ARHGAP31 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label ARHGAP31 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...